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Abstract
In recent years, the use of adaptive design methods in pharmaceutical/clinical research and development has
become popular due to its flexibility and efficiency for identifying potential signals of clinical benefit of the test
treatment under investigation. The flexibility and efficiency, however, increase the risk of operational biases with
resulting decrease in the accuracy and reliability for assessing the treatment effect of the test treatment under
investigation. In its recent draft guidance, the United States Food and Drug Administration (FDA) expresses
regulatory concern of controlling the overall type I error rate at a pre-specified level of significance for a clinical
trial utilizing adaptive design. The FDA classifies adaptive designs into categories of well-understood and less well-
understood designs. For those less well-understood adaptive designs such as adaptive dose finding designs and
two-stage phase I/II (or phase II/III) seamless adaptive designs, statistical methods are not well established and
hence should be used with caution. In practice, misuse of adaptive design methods in clinical trials is a concern to
both clinical scientists and regulatory agencies. It is suggested that the escalating momentum for the use of
adaptive design methods in clinical trials be slowed in order to allow time for development of appropriate
statistical methodologies.
Keywords: Flexibility, Efficiency, Well-understood design, Less well-understood design, Group sequential design,
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Introduction
In pharmaceutical/clinical research and development,
clinical trials are conducted for evaluation of safety and
efficacy of a test treatment under investigation. In the
past several decades, it has become evident that
increased spending does not reflect an increased success
rate in new product development. Woodcock (2004)
suggested that the low success rate of pharmaceutical
development could be due to several issues. One of the
most critical of these is the rapidly escalating costs of
the clinical trials required for regularity approval As a
result, the United States Food and Drug Administration
(FDA) kicked off a Critical Path Initiative in early 2000s
to assist sponsors in identifying the scientific challenges
underlying the medical product pipeline problems [1].
In 2006, the FDA released a Critical Path Opportu-
nities List that outlines 76 initial projects (six broad
topic areas) to bridge the gap between the quick pace of
new biomedical discoveries and the slower pace at
which those discoveries are currently developed into
therapies. Among the 76 initial projects, the FDA calls
for advancing innovative trial designs, especially for the
use of prior experience or accumulated information in
trial design, which was interpreted as an encouragement
for the use of adaptive design methods in clinical trials.
Since then, the potential use of adaptive clinical designs
in clinical research have been increasingly discussed due
to its flexibility and efficiency for identifying potential
signal or trend of clinical benefit of the test treatment
under investigation [2,3]. In addition, it is believed that
the use of adaptive trial design will not only increase the
probability of success of clinical development but also
shorten the time of clinical development.
In February 2010, a draft guidance on adaptive design
clinical trials by the FDA was circulated for comments.
This draft guidance is a document describing the poten-
tial use of adaptive designs in clinical trials. It is gener-
ally viewed as supportive of the use of adaptive designs
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i sn o tas p e c i f i cg u i d a n c ef o rt h ei m p l e m e n t a t i o no f
adaptive designs in clinical trials [4,5]. It, however,
should be noted that adaptive designs have been used at
times in confirmatory contexts, for the most part cau-
tiously, limited to changes such as sample size re-esti-
mation and treatment arm consolidation in the early
phase of clinical development where there is more
uncertainty and regulatory concerns are minimized. The
FDA classifies adaptive designs into well-understood
designs and less well-understood designs. Well-under-
stood design refers to the typical group sequential
design, which has been employed in clinical research for
years. Less well-understood designs include the adaptive
dose finding and two-stage phase I/II (or II/III) seamless
adaptive designs. Many scientific issues surrounding the
less well-understood designs are posted in the draft gui-
dance without recommendations for resolution. This
raises the question whether the use of adaptive design
methods in clinical trials (especially for those less well-
understood designs) is ready for implementation in
practice.
In the next section, a definition of adaptive design by
the FDA and most commonly considered adaptive
designs are brief described. Sections 3 provide clinical,
statistical, and regulatory perspectives on the use of
adaptive design methods in clinical trials, respectively.
Section 4 discusses major challenges and obstacles when
implementing adaptive designs in clinical trials. A con-
cluding remark and future perspectives regarding adap-
tive clinical trial designs are given in Sections 5 and 6,
respectively.
Adaptive Clinical Trial Designs
What is adaptive design?
In clinical trials, it is not uncommon to modify trial
and/or statistical procedures through protocol amend-
ments during the conduct of clinical trials based on
either external information (e.g., safety concerns raised
in the medical literature) or review of interim data. The
purpose is not only to efficiently identify clinical benefits
of the test treatment under investigation, but also to
increase the probability of success of clinical develop-
ment. In this article, we will refer to the adaptations (or
modifications) made to the trial and/or statistical proce-
dures as the adaptive design methods. Thus, an adaptive
design could be defined as a design that allows modifica-
tions to a trial and/or the statistical procedures of a trial
after its initiation without undermining the validity or
integrity of the trial [6]. In their recent publication, with
the emphasis on by design adaptations only (rather than
ad hoc adaptations), the Pharmaceutical Research Man-
ufacturer Association (PhRMA) Working Group on
Adaptive Design refers to an adaptive design as a
clinical trial design that uses accumulating data to deter-
mine how to modify aspects of an ongoing study with-
out undermining the validity and integrity of the trial
[7]. In contrast the FDA defines an adaptive design as a
study that includes a prospectively planned opportunity
for modification of one or more specified aspects of the
study design and hypotheses based on analysis of
(usually interim) data from subjects in the study [4]. An
adaptive design is also known as a flexible design by the
European Medicines Agency (EMA) [8,9].
Types of adaptive designs
By design adaptations may not be as flexible as they are
meant to be when there is a prospectively planned adap-
tation embedded in the original statistical plan. In con-
trast, ad hoc adaptations via protocol amendments
reflect real clinical practices, which may give clinical
investigators increased flexibility for identifying possible
clinical benefits of the test treatment under investiga-
tion. However, ad hoc adaptations may also increase the
chance of misuse or abuse of the adaptive trial designs.
Retrospective adaptations are used to develop the most
appropriate statistical methods for data analysis without
undermining the validity and integrity of the trial. The
most commonly considered adaptive designs in clinical
trials include, but are not limited to: an adaptive rando-
mization design, a group sequential design, a flexible
s a m p l es i z er e - e s t i m a t i o nd e s i g n( a l s ok n o w na sa nN -
adjustable design), a drop-the-loser design (also known
as a pick-the-winner design), an adaptive dose finding
(escalation) design, a biomarker-adaptive design (also
known as an enrichment target clinical trial design), an
adaptive treatment-switching design, a hypothesis-adap-
tive design, a two-stage phase I/II (or phase II/III) seam-
less adaptive trial design, and a multiple adaptive design
(which is a combination of any of the above adaptive
designs). Detailed description of these adaptive designs
and their advantages and limitations can be found in
[2,3].
Some examples
In this section, to provide a better understand of adap-
tive designs in clinical trials, examples concerning the
use of well-understood adaptive design and less well-
understood adaptive design in clinical research and
development are given.
Example 1: Group sequential design (well-under-
stood design) - Suppose a pharmaceutical company is
interested in conducting a clinical trial utilizing a group
sequential trial design with a planned interim analysis to
assess safety (tolerability) and efficacy (failure rate) of a
study drug in treating patients with asymptomatic ade-
novirus viremia. The primary objective is to test for sta-
tistical significance in the detection of a 25% difference
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assuming that the failure rate of the placebo group is
50%. If possible the sponsor would like to stop the trial
early due to efficacy/futility. Sample size calculation was
performed based on the primary study endpoint of rate
of failure at 12 weeks post randomization using the
method of individual p-values proposed by [10]. At
interim analysis, the following stopping rules based on
individual p-values are considered:
Stop for efficacy if T1 ≤ a1;
Stop for futility if T1 ≤ b1;
Continue with adaptation if a1 <T1 ≤ b1;
where a1 and b1 (a1 <b1) are the efficacy and futility
boundaries at interim (stage 1), respectively, and T1 is
the test statistic (based on individual p-value) to be used
at interim analysis. Based on the above stopping bound-
aries and individual p-values, it can be shown that a =
a1+a2(b1-a1). Thus, we choose the efficacy and futility
boundaries as follows
α1 =0 . 0 0 5 ,β1 = 0.40,α2 = 0.0506
for controlling the overall type I error rate at the 5%
level of significance, where a2 is the significance level at
the end of the study. Table 1 gives sample sizes required
for achieving various desired powers (e.g., 80%, 85%, and
90%) under the assumptions that (1) the failure rate of
the placebo group is 60%, 55%, 50%, 45%, or 40% (2)
the clinically meaningful difference is 50% of the placebo
failure rate, and (3) the randomization ratio is either 1:1
or 2:1. As it can be seen from Table 1 a total of 132
subjects (88 subjects in the test group and 44 in the pla-
cebo group) are required for achieving an 80% power
for detecting a 25% difference in failure rate at the 5%
level of significance assuming that (1) the randomization
ratio is 2:1 and (2) the true failure rate of the placebo is
50%.
As discussed above, group sequential design enjoys the
flexibility/benefits of stopping the trial early and sample
size re-estimation. However, how to control the overall
type I error rate at a pre-specified level of significance
when there is a possible population shift due to (i) addi-
tional adaptations at interim and/or (ii) protocol amend-
ments has become one of the major challenges/obstacles
for the well-understood design.
Example 2: Adaptive dose escalation design (less
well-understood design) - Suppose a pharmaceutical
company is planning a phase I dose escalation study to
evaluate an intravenous administration of a study drug
for patients with a specific type of cancer. The primary
objective of this dose escalation trial is to determine the
maximum tolerable dose (MTD) of the study drug. The
identified MTD will be considered as the optimal dose
for subsequent clinical trials conducted for later phase
clinical development. The sponsor has two choices for
the intended dose escalation study: an algorithm-based
traditional dose escalation rule (TER) design and a
model-based continual re-assessment method (CRM)
design.
For the algorithm-based trial design, the traditional
escalation rule is to enter three patients at a new dose
level and then enter another three patients when a dose
limiting toxicity (DLT) is observed. The assessment of
the six patients is then performed to determine whether
the trial should be stopped at the level or to escalate to
the next dose level. Thus, this trial design is also known
as the 3+3 TER design. The model-based CRM trial
design with n patients per dose level, i.e., CRM(n), can
be summarized by the following steps:
Step 1: Selecting the starting dose;
Step 2: Determining dose range and number of dose
levels (usually 6-8 dose levels); In the CRM trial design,
the next patient will be assigned to the dose level which
is close to the estimated MTD from the updated dose-
toxicity model.
Step 3: Primary assumption on the dose-toxicity
model. The commonly considered dose-toxicity model
in cancer research is p(x)=[ 1 + b exp(-ax)]
-1,w h e r ep(x)
is the probability of toxicity with dose x.U n d e rt h e
above dose-toxicity model, the MTD can be estimated
by MTD =
1
a
ln

bθ
1 − θ

,w h e r eθ is the probability of DLT
(DLT rate) at MTD.
Step 4: Pre-specified dose escalation rule. For example,
the CRM will employ the dose escalation rules such as
the number of dose levels that are allowed to be skipped
is 0 and/or the minimum number of patients treated at
current dose level before escalating to the next dose
level.
Table 1 Sample Size Calculation
Randomization Ratio Failure Rate Power
Placebo Test 80% 85% 90%
1:1 60% 30% 80 (40) 90 (45) 106 (53)
55% 27% 90 (45) 102 (51) 120 (60)
50% 25% 110 (55) 126 (63) 148 (74)
45% 22% 126 (63) 144 (72) 168 (84)
40% 20% 158 (79) 180 (90) 212 (106)
2:1 60% 30% 93 (62) 105 (70) 123 (82)
55% 27% 105 (70) 120 (80) 141 (94)
50% 25% 132 (88) 150 (100) 174 (116)
45% 22% 150 (100) 171 (114) 201 (134)
40% 20% 189 (126) 216 (144) 255 (170)
Note: 1. The numbers are the total sample sizes required, while the numbers
in the parentheses are the sample sizes required for the test group.
2. Sample sizes do not adjust for possible dropouts.
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maximum number of patients at a dose level have
reached 6 subjects, we claim that the MTD has been
achieved.
Typical adaptations applies to the 3+3 TER trial
design include (1) the flexibility of dose de-escalation
and (2) the extension of the 3+3 TER to the a+b TER
with and without dose de-escalation. For the CRM, a
Bayesian approach is commonly considered. In clinical
trials, although these two trial designs are commonly
considered, little discussion regarding criteria for design
selection are available in the literature.
For selecting an appropriate study design, two criteria
based on a fixed sample size approach and a fixed prob-
ability of correctly identifying the MTD are commonly
considered. For a fixed sample size, the optimal design
can be chosen based on one of the following
(1) Number of DLTs expected;
(2) Bias and variability of the estimated MTD;
(3) Probability of observing DLT prior to MTD;
(4) Probability of correctly identifying the MTD.
In other words, we may choose the design with the
highest probability of correctly identifying the MTD. If
it is undesirable to have patients experience the DLT,
we may choose the design with the smallest number of
DLT expected. In practice, we may compromise by
choosing the most appropriate design to meet our need.
On the other hand, for a fixed probability of correctly
identifying the MTD, the optimal design can be chosen
based on one of characteristics described above. Thus,
we may choose the design with the smallest probability
of observing DLT prior to MTD. Similarly, we may
compromise the above criteria for choosing the most
appropriate design to meet our need.
For design selection of the proposed dose escalation
trial, a clinical trial simulation was conducted under the
assumptions that (1) the total simulation runs is 5,000,
(2) the initial dose is 0.3 mCi/kg, (3) the dose range is
from 0.3 mCi/kg to 2.8 mCi/kg assuming that the MTD
is at 2.5 mCi/kg with a total number of dose levels of 6,
(4) algorithm-based 3+3 TER with and without de-esca-
lation are considered, (5) maximum dose de-escalation
allowed is 1, (6) CRM(n) with n = 1, 2, and 3 are con-
sidered, where n is the number of subjects per dose
level, (7) logistic dose-toxicity model is assumed, (8)
DLT rate at MTD is assumed to be 1/3 = 33%, (9) Baye-
sian approach with uniform prior is considered for esti-
mation of the parameters of the dose-toxicity model,
(10) number of doses allowed to skip is 0. The results
are summarized in Table 2. As a result, CRM(2) trial
design is chosen for the proposed dose escalation trial
for identifying the MTD.
Note that the CRM(n) with n = 2 will provide a more
accurate and reliable assessment of the dose-toxicity
model as compared to that of the CRM(n) with n = 1.
Although the CRM(n) (in conjunction with Bayesian
approach) provides a more accurate and reliable
approach for identifying the MTD, the validation of the
dose-toxicity mode, the selection of appropriate prior,
p o s s i b l ed o s ej u m pa n do v e r d o s eh a v eb e c o m em a j o r
challenges/obstacles for the investigators.
Example 3: Two-stage phase II/III adaptive design
(less well-understood design) - A pharmaceutical com-
pany is interested in conducting a clinical trial utilizing
a two-stage seamless adaptive design for evaluation of
safety (tolerability) and efficacy of a test treatment for
patients with hepatitis C virus (HCV) infection. The
study will consist of two stages at which the first stage
is for dose selection and the second stage is for estab-
lishment of non-inferiority of the selected dose from the
first stage as compared to the standard of care therapy
(control). The primary objectives of the study then con-
tain study objectives at both stages. For the first stage,
the primary objective is to select the optimal dose as
compared to the standard of care therapy, while the pri-
mary objective of the second stage is to establish non-
inferiority of the selected dose as compared to the stan-
dard of care therapy. The treatment duration is 48
weeks of treatment followed by a 24 weeks follow-up.
The primary study endpoint is the sustained virologic
response (SVR) at week 72, which is defined as an unde-
tectable HCV RNA level (< 10 IU/mL) at week 72.
The proposed two-stage seamless adaptive design is
b r i e f l yo u t l i n eb e l o w :S t a g e1 :T h i ss t a g ei saf i v e - a r m
Table 2 Summary of Simulation Results
Design # Patients Expected (N) # of DLT Expected Mean MTD (SD) Prob. of Selecting Correct MTD
“3+3”
TER
15.96 2.8 1.26 (0.33) 0.526
“3+3”
STER*
17.56 3.2 1.02 (0.30) 0.204
CRM(1) 10.60 3.4 1.51 (0.08) 0.984
CRM(2) 13.57 2.8 1.57 (0.20) 0.884
CRM(3) 16.37 2.7 1.63 (0.26) 0.784
* Allows dose de-escalation
CRM(n) = CRM with n patients per dose level; Uniform prior was used.
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test treatment. Qualified subjects will be randomly
assigned to one of the five treatment groups at a
1:1:1:1:1 ratio. After all Stage 1 subjects have completed
Week 12 of the study, an interim analysis was per-
formed. Based upon the safety results of this analysis as
well as virologic response at Weeks 12 and 24, Stage 1
subjects who have not yet completed the study protocol
will continue with their assigned therapies for the
remainder of the planned 48 weeks, with final follow-up
at Week 72. An optimal dose will be selected based on
the interim analysis results of the 12 week early virolo-
g i cr e s p o n s e( E V R ) ,w h i c hi sd e f i n e da s2 - l o g 1 0r e d u c -
tion in HCV RNA level at Week 12, assuming that the
12 week EVR is predictive of 72 week SVR. The 12
week EVR is considered as a surrogate endpoint for the
primary endpoint of 72 week SVR. Under this assump-
tion, an optimal dose will be selected using precision
analysis under some pre-specified selection criteria. In
other words, the dose group with highest confidence
level for achieving statistical significance (i.e., the
observed difference is not by chance alone) will be
selected. The selected dose will then proceed to testing
for non-inferiority compared to standard of care in
S t a g e2 .S t a g e2 :T h i ss t a g ew i l lb ean o n - i n f e r i o r i t y
comparison of the selected dose from Stage 1. A sepa-
rate cohort of subjects will be randomized to receive
either the selected dose from Stage 1 or the standard of
care treatment as given in Stage 1 in a 1:1 ratio. A sec-
ond interim analysis will be performed when all Stage 2
subjects have completed Week 12 and 50% of the sub-
jects (Stage 1 and Stage 2 combined) have completed 48
weeks treatment and follow-up of 24 weeks. Depending
on the results of this analysis, including the virologic
response at Weeks 12 and 24, sample size re-estimation
will be performed to whether additional subjects are
needed in order for achieving the desired power for
establishment of non-inferiority for the selected dose.
In both stages, subjects who do not meet the study
criteria for virologic response at Weeks 12 and 24, and
those who do meet these criteria but then relapse at any
later time through study Week 72, will discontinue
study treatment and will be offered treatment, off proto-
col, with standard of care. For the two planned interim
analyses, the incidence of EVR as well as safety data,
will be reviewed by an independent data safety monitor-
ing board (DSMB). The commonly used O’Brien-Flem-
ing boundaries will be applied for controlling the overall
Type I error rate at 5% [11,12]. Adaptations such as
stopping the trial early, discontinuing selected treatment
arms, and re-estimating the sample size may be applied
as recommended by the DSMB. Stopping rules for the
study will be designated by the DSMB, based on their
ongoing analyses of the data and as per their charter.
In clinical research and development, the use of two-
stage phase I/II or phase II/III adaptive seamless design
has become very popular due to its flexibility and effi-
ciency for achieving the study objectives of the intended
trials. However, the development of appropriate and
valid statistical methods and the control of the overall
type I error under the complexity of the less well-under-
stood design are major challenges/obstacles to clinical
scientists.
2.4 Benefits of adaptive designs
Possible benefits for the use of adaptive design methods
in clinical trials include that (1) it allows the investigator
to correct wrong assumptions made at the beginning of
the trial, (2) it helps to select the most promising option
early, (3) it makes use of emerging external information
to the trial, (4) it provides the investigator the opportu-
nity to react earlier to surprise (either positive or nega-
tive), and (5) it may shorten the development time and
consequently speed up development process. In sum-
mary, the use of adaptive design methods in clinical
research and development provides the investigator the
second chance to modify or re-design the trial after see-
ing data from the trial itself at interim or externally as
recommended by the independent data monitoring
committee (IDMC) of the study.
While enjoying the flexibility and possible benefits of
adaptive design methods in clinical trials, it should be
noted that more flexibility could lead to a less well-
understood design as described in the FDA draft gui-
dance. A less well-understood adaptive design is often
more flexible and yet more complicated. Under a com-
plicated and less well-understood adaptive design, statis-
tical inference is often difficult, if not impossible, to
obtain although valid statistical inferences for some less
well-understood designs are available in the literature.
As an example, Table 3 provides a summary of flexibil-
ities and possible benefits of some less well-understood
adaptive designs such as an adaptive randomization
design, an adaptive dose finding design, and a two-stage
phase I/II (or phase II/III) seamless adaptive design that
are commonly considered in pharmaceutical/clinical
research and development.
Clinical/Statistical and Regulatory Perspectives
Clinical Operation Perspectives
From clinical operation perspectives, the use of adaptive
design methods in clinical trials does reflect real clinical
practices in clinical research and development. In clini-
cal practice, the prospective (or by design) adaptations
of unequal ratio of randomization, data safety monitor-
ing, interim analysis for efficacy, stopping the trial early
due to safety and efficacy/futility, and sample size re-
estimation are commonly considered at the stage of
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is not uncommon that some concurrent (ad hoc) adap-
tations such as modification of inclusion/exclusion cri-
teria, dose regimen/duration, and primary study
endpoints and/or hypotheses are implemented through
protocol amendments due to slow enrollment, safety
concern, and the issue of lack of efficacy, respectively.
Note that frequent ad hoc adaptations without consid-
eration of the statistical implications have provided an
argument for using prospectively planned adaptive
design methods in clinical trials. At the end of the
study, some retrospective adaptations on statistical ana-
lysis plan of the data collected from the trial are often
applied prior to database lock or data unblinding.
As indicated earlier, the use of adaptive clinical trial
design is very attractive due to its flexibility and effi-
ciency for identifying optimal clinical benefits of a test
treatment under investigation especially when only lim-
ited resources and/or time are available. However,
before an adaptive design can be implemented, the prac-
tical issues of feasibility, validity and robustness, which
have impact on the data quality and the integrity of the
trial, are necessarily addressed from clinical perspectives.
These practical issues are briefly described below.
For feasibility, the following questions arise and need
to be addressed before the interested adaptive design
can be implemented [13]: (1) Do the possible benefits
outweigh the extra efforts required for implementation
of the adaptive design? (2) Does the level of difficulty
and the associated cost justify the gain from implement-
ing the adaptive design? (3) Does the implementation of
adaptive design delay patient recruitment and prolong
study duration? (4) How often are the unblinded ana-
lyses practical and to whom should the data be
unblinded? (5) How should the impact of the data mon-
itoring committee’s (DMC) decision regarding the trial
(e.g., recommending an early stopping or other adapta-
tions due to safety concern) be considered at the design
stage?
For the issue of validity, it is reasonable to ask the fol-
lowing questions: (1) Does the unblinding cause poten-
tial bias in treatment assessment? (2) Does the
implementation of an adaptive design destroy the ran-
domness? For example, response-adaptive randomization
is used to assign more patients to the superior treatment
groups by changing the randomization schedule. How-
ever, for ethical reasons, the patients should be informed
that the later they come into the study, the greater the
chance of being assigned to the superior groups. For
this reason, patients may prefer to wait for late entry
into the study. This could cause bias because sicker
patients might enroll earlier just because they cannot
wait. When this happens, the treatment effect is con-
founded by the patient’s disease background. A similar
bias could occur for a drop-losers design and other
adaptive designs.
Regarding the issue of robustness, virtually without
exception, a trial cannot be conducted exactly as speci-
fied in the protocol. In practice, it is helpful to assess
the issue of robustness by addressing the following
questions. First, would protocol deviations and/or viola-
tions invalidate the adaptive trial design employed? For
example, if an actual interim analysis was performed at
a different (information) time that the scheduled one,
how does it impact the type-I error of the adaptive
design? How does an unexpected DMC action affect the
power and validity of the design? Would a protocol
amendment such as endpoint change or inclusion/exclu-
sion change invalidate the design and analysis? Would
delayed responses diminish the advantage of implement-
ing an adaptive design such as continued re-assessment
method (CRM) in an adaptive dose-escalation design
Table 3 Summary of Flexibility/Benefits and Challenges/Obstacles of Various Less Well-Understood Adaptive Designs
Design Flexibility/Benefits Challenges/Obstacles
Adaptive
Randomization
Design
■ Unequal probability of treatment assignment
■ Assign subjects to more promising treatment arm
■ Randomization schedule not available prior
to the conduct of the trial
■ Not feasible for large trials or trials with
long treatment duration
■ Statistical inference is often different, if not
impossible, to obtain
Adaptive Dose
Finding Design*
■ Drop inferior dose group early
■ Modify/add additional dose groups
■ Increase the probability of correctly identifying the MTD with limited
number of subjects
■ Selection of initial dose
■ Selection of dose range under study
■ Selection criteria and decision rule
■ Risk of dropping promising dose groups
Two-stage Seamless
Adaptive Design
(either phase I/II or
phase II/III)
■ Combine two studies into a single study
■ Fully utilize data collected from both stages
■ Reduce lead time between studies
■ Shorten the development time
■ Additional adaptations such as drop-the-loser, adaptive randomization, and
adaptive hypotheses may be applied at the end of the 1
st stage
■ The control of the overall type I error rate
■ Sample size calculation/allocation
■ How to perform analysis based on
combined data collected from both stages?
■ Is the O’Brien-Fleming type of boundaries
feasible?
*For example, adaptive dose escalation designs for cancer trials.
Chow and Corey Orphanet Journal of Rare Diseases 2011, 6:79
http://www.ojrd.com/content/6/1/79
Page 6 of 10and trials with a survival endpoint? In addition, what
level of modifications to the trial would be acceptable to
the regulatory authorities? Does the adaptive design
have adequate theoretical support? Does implementation
of the adaptive design deviate from the theoretical
model? Is the adaptive design robust against major pro-
tocol deviations? Does the data unblinding actually
cause bias in assessment?
Statistical Perspectives
From a statistical point of view, major adaptations or
modifications to trial and/or statistical procedures could
(1) introduce operational bias/variation to data collec-
tion, (2) result in a shift in the target patient population
in terms of either location or scale parameter, and (3)
lead to inconsistency between hypotheses to be tested
and the corresponding statistical tests.
In clinical trials, any modifications made to the trial
and/or statistical procedures may introduce operational
bias and/or variation to the data collection. The sources
of bias/variation can be classified into four categories,
namely (1) expected and controllable such as changes in
laboratory testing procedures and/or diagnostic proce-
dures, (2) expected but not controllable such as change
in study dose and/or treatment duration, (3) unexpected
but controllable such as patient non-compliance, and (4)
unexpected and uncontrollable which is the random
error in observing the clinical responses/outcomes [14].
For good clinical practice, we should make every
attempt not only to identify but also to minimize/con-
trol possible operational bias/variation whenever
possible.
As indicated in [2], significant or major modifications
made to the trial could result in a shift in target patient
population (i.e., from the target patient population to a
similar but slightly different target patient population).
It is then a concern whether (significant or major)
changes made to the trial have led to a totally different
trial with a similar but different target patient popula-
tion. Consequently, we may not be able to answer the
medical/scientific questions that the original trial
intended to address. Thus, it is of interest to determine
whether statistical inference obtained based on clinical
data collected from the actual patient population could
be applied to the originally planned target patient
population.
In addition, the misuse and/or abuse of the adaptive
design methods in clinical trials could lead to inconsis-
tencies between hypotheses to be tested and the corre-
sponding statistical tests where (1) there are wrong tests
for the right hypotheses (the validity is a concern), (2)
there are right tests for the wrong hypotheses (an evi-
dence of the misuse of certain adaptations), (3) there are
wrong tests for the wrong hypotheses (an evidence of
abuse of the adaptive design methods), and (4) there are
right tests for the right hypotheses with insufficient
power [14].
In clinical investigation, a pre-study power analysis for
sample size calculation is always performed for achiev-
ing a desired power for correctly detecting a clinically
meaningful difference (or treatment effect) at a pre-spe-
cified level of significance. The ultimate goal is to make
sure that the observed difference has both clinical and
statistical meaning in the sense that (1) it is of clinical
importance, (2) it is not by chance alone, and (3) it is
reproducible. The pre-study power analysis can only be
done under a valid statistic derived under the null
hypothesis. Thus, for a given adaptive design, valid sta-
tistical methods are necessary to ensure the success of
the clinical trials utilizing adaptive trial designs, espe-
cially for those less well-understood adaptive designs.
Regulatory Perspectives
As indicated earlier, the use of adaptive design methods
based on accrued data in clinical trials may introduce
operational bias, which is a great concern to the regula-
tory agencies in the review/approval process of the regu-
latory submission. One of the major concerns is that the
use of adaptive trial designs (especially for those less
well-understood designs) may not be able to preserve
the overall type I error rate at the pre-specified level of
significance. In addition, p-values may not be correct
and the corresponding confidence intervals for the treat-
ment effect may not be reliable. Moreover, adaptations
m a yr e s u l ti nat o t a l l yd i f f e r e n tt r i a lt h a ti su n a b l et o
address the medical questions that the original study
intended to answer.
I nc l i n i c a lt r i a l s ,i ti sr e c o g n i z e dt h a tt h eu s eo fa d a p -
tive design methods (either by design adaptation or ad
hoc adaptation) may introduce operational biases such
as selection bias, method of evaluations, early withdra-
wal, and modification of treatments. Consequently, the
adaptation employed may inflate type I error rate [15].
In practice, operational biases could be translated to
information (assessment) biases, which may include
patient enrollment, differential dropouts in favor of one
treatment, crossover to the other treatment, protocol
deviation due to additional medications or treatments,
and differential assessment of the treatments [16]. Com-
monly seen adaptations which have an impact on the
type I error rate include, but are not limited to, sample
size adjustment at interim, sample size allocation to
treatments, delete/add or change treatment arms, shift
in target patient population such as changes in inclu-
sion/exclusion criteria, change in statistical test strategy,
change in study endpoints, and change in study objec-
tives such as the switch from a superiority trial to a
non-inferiority trial [15]. As a result, it is difficult to
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treatments under study [16].
These regulatory concerns have led to the develop-
ment of valid statistical methods under various less
well-understood adaptive designs. As a result, the esca-
lating momentum behind adaptive clinical trial designs
continues moving forward since the FDA draft guidance
was distributed for comments in February, 2010.
Major Challenges and Obstacles
Despite the attractive characteristics of flexibility and
efficiency of adaptive design trial designs in clinical
trials, some concerns regarding the quality, validity and
integrity of the trials arise, which have resulted in major
challenges and obstacles to the investigators, clinical
scientists and biostatisticians when implementing adap-
tive design methods in clinical trials. In this section,
some challenges and obstacles, clinical trial simulation,
and software application packages are discussed (see
also Table 3).
Well-understood design
In clinical trials, a group sequential design is often
considered for (1) early stopping for clinical benefit or
harm, (2) early stopping for futility, (3) sample size
re-estimation, and (4) re-designing the study in mid-
stream [17]. As indicated in the FDA draft guidance,
group sequential designs are considered well-under-
stood when design characteristics 1 or 2 are applied
but not when design characteristics 3 or 4 are incor-
porated. The well-understood group sequential design
is very popular due to the following two reasons.
First, clinical endpoint is a moving target. The spon-
sors and/or investigators may change their mind
regarding clinically meaningful effect size after the
trial starts. Second, it is a common practice to request
a small budget at the design and then seek for supple-
mental funding for increasing the sample size after
seeing the interim data. To protect the overall type I
e r r o rr a t ei na na d a p t i v ed e s i g nw i t hr e s p e c tt o
changes in some design parameters, many authors
have proposed procedures using observed treatment
effects. This leads to the justification for the com-
monly used two-stage adaptive design, in which the
data from both stages are independent and the first
data are used for adaptation. When there is a shift in
the location and/or scale parameters of the target
patient population due to major changes in protocol
amendments (e.g., major changes in eligibility cri-
teria), however, standard methods for the well-under-
stood group sequential design may not be valid. In
this case, “How to protect the overall type I error rate
with respect to changes in some design parameters?”
has become a challenge to biostatisticians.
Less well-understood designs
In practice, two-stage phase II/III seamless adaptive
designs with different study objectives and/or different
study endpoints at different stages are considered less
well-understood designs in the sense that (1) valid sta-
tistical methods are yet to be developed, and (2) the
impact of additional adaptations on statistical inference
is unknown [18,19]. Under the two-stage adaptive
design, “How to perform sample size calculation/alloca-
tion at the planning stage?”, “How to control the overall
type I error rate at a pre-specified level of significance?”,
and “How to combine data collected from both stages for
a final data analysis?” are major challenges to biostatis-
ticians. In addition, it is a concern when there is a
population shift due to protocol amendments, which
will make the less well-understood design even more
complicated and lesser well-understood.
Clinical Trial Simulation
Clinical trial simulation is a process that uses computers
to mimic the conduct of a clinical trial by creating vir-
tual patients to extrapolate (or predict) clinical out-
comes for each virtual patient based on the pre-
specified models [20,21]. The primary objective of clini-
cal trial simulation is multi-fold. First, it is used to
monitor the conduct of the trial, project outcomes,
anticipate problems and recommend remedies before it
is too late. Second, it is used to extrapolate (or predict)
the clinical outcomes beyond the scope of previous stu-
dies from which the existing models were derived using
the model techniques. Third, it is used to study the
validity and robustness of the trial under various
assumptions of study designs. Clinical trial simulation is
often conducted to verify (or confirm) the models
depicting the relationships between the inputs such as
dose, dosing time, patient characteristics, and disease
severity and the clinical outcomes such as changes in
the signs and symptoms or adverse events within the
study domain. In practice, clinical trial simulation is
often considered a way of predicting potential clinical
outcomes under different assumptions and various
design scenarios at the planning stage of a clinical trial
for a better planning of the actual trial. However, clini-
cal trial simulation is useful only when based on a well-
established predictive model under certain assumptions
[21]. “How to validate the assumed predictive model for
clinical trial simulation?” is a major challenge to both
investigators and biostatisticians.
Software Packages
As indicated earlier, more adaptations give the investiga-
tor more flexibility in identifying best clinical benefits of
the test treatment under investigation. However, a mul-
tiple adaptive design with more adaptations could be
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cal methods for assessment of the treatment effect may
not be available and are difficult, if not impossible, to
obtain. Thus, one of the major obstacles for implement-
ing adaptive design methods in clinical trials is that
appropriate statistical methods are not well established
with respect to various adaptations. Current software
packages such as SAS cannot be applied directly and
hence are not helpful. Although there are some software
available in the marketplace such as ExpDesign Studio
[22], EastSurvAdapt [23], and ADDPLAN (http://www.
addplan.com), which cover certain types of adaptive trial
designs, new software packages for adaptive design
methods in clinical trials are necessary to assist in
implementing adaptive trial designs in clinical trials [24].
An overview of software available for group sequential
and adaptive designs can be found in [25].
Concluding Remarks
In clinical trials, although the flexibility of modifying
study parameters is very attractive to clinical scientists,
several scientific (clinical, statistical, and regulatory)
questions/concerns arise. First, what level of modifica-
tions to the trial procedures and/or statistical proce-
dures would be acceptable to the regulatory authorities?
Second, what are the regulatory requirements and stan-
dards for the review and approval process of clinical
data obtained from adaptive clinical trials with different
levels of modifications to trial procedures and/or statisti-
cal procedures of on-going clinical trials? Third, has the
clinical trial become a totally different trial after the
modification of the trial procedures and/or statistical
procedures for addressing the study objectives of the
originally planned clinical trial? These concerns should
be addressed by the regulatory authorities before the
adaptive design methods can be widely accepted in clini-
cal research and development. As a result, guidelines for
specific adaptive design methods must be developed in
order to avoid every intentional or unintentional manip-
ulation of the adaptive design results in clinical trials.
The guidelines should describe in detail not only the
standards for use of specific adaptive design methods in
clinical trials, but also the level of modification in an
adaptive design that is acceptable to the regulatory
agencies. In addition, any changes in the process of reg-
ulatory review/approval should be clearly indicated in
such guidelines. It should be noted that the adaptive
design methods have been used in the review/approval
process of regulatory submissions for years, though it
may not have been recognized until recently. As indi-
cated earlier, most adaptive clinical trials designs for
clinical investigation of a test treatment under investiga-
tion that are of particular interest to the investigators
are considered less well-understood designs. For some
(complicated) less well-understood designs, statistical
methods are yet to be developed. The use of an inde-
pendent data safety monitoring board (DSMB) will not
only help to prevent the investigator from misuse and/
or abuse of the adaptive design methods, but also to
ensure the quality, validity, and integrity of the trials uti-
lizing adaptive designs [26].
Future Perspectives
We are moving in the right direction and yet there is
still a long way to go until we are able to address all of
the scientific issues from clinical, statistical, and regula-
tory perspectives as described earlier. Detailed design-
specific guidances (e.g., guidances regarding sample size
calculation/allocation and statistical/clinical considera-
tions for a two-stage phase I/II or phase II/III seamless
adaptive trial design) must be developed by the regula-
tory agencies before implementation of adaptive design
methods in pharmaceutical/clinical research and devel-
opment. In addition, qualification, composition, role/
responsibility, and function/activity of an independent
data monitoring committee for implantation of adaptive
trial design need to be established for an objective and
unbiased assessment of the treatment effect of the drug
under investigation. Thus, from future perspectives, it is
suggested that the escalating momentum for the use of
adaptive design methods in clinical trials proceed with
caution. At the same time, valid statistical methods for
interested adaptive designs with various adaptations
should be developed to prevent the possible misuse and/
or abuse of the adaptive design methods in clinical
trials.
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